Table 2.
Controls | T2DM without LGE | T2DM with ischemic LGEa | T2DM with non-ischemic LGE | P-valueb | P-valuec | |
---|---|---|---|---|---|---|
Cardiovascular magnetic resonance imaging | ||||||
LV end-diastolic volume, mL | 166 ± 39 | 149 ± 32 | 172 ± 50 | 151 ± 27 | 0.03 | 0.8 |
LV end-diastolic volume/BSA, mL/m2 | 83 ± 13 | 70 ± 13 | 79 ± 18 | 69 ± 12 | < 0.0001 | 0.7 |
LV end-systolic volume, mL | 63 ± 15 | 54 ± 17 | 79 ± 34 | 55 ± 22 | 0.0005 | 0.9 |
LV end-systolic volume/BSA, mL/m2 | 31 ± 6 | 25 ± 8 | 36 ± 14 | 25 ± 10 | < 0.0001 | 0.8 |
LV mass, g | 121 ± 25 | 133 ± 33 | 163 ± 52 | 150 ± 34a | 0.0003 | 0.02 |
LV mass/BSA, g/m2 | 60 ± 8 | 62 ± 13 | 75 ± 19 | 68 ± 13a | 0.0007 | 0.03 |
LV ejection fraction, % | 62.3 ± 3.9 | 64.0 ± 6.4 | 55.5 ± 9.0 | 64.5 ± 9.6 | < 0.001 | 0.8 |
LA volume, mL | 104 IQR86.2–115.6 | 91 IQR75.2–100.0 | 106 IQR77.9–134.3 | 102 IQR84.6–115.2a | 0.002 | 0.049 |
LA volume/BSA, mL/m2 | 50 IQR47–54 | 41 IQR36–47 | 48 IQR37–59 | 43 IQR39–52 | < 0.0001 | 0.15 |
LV ECV, % | 26.1 ± 1.5 | 28.8 ± 2.7 | 32.2 ± 3.8 | 30.4 ± 3.1a | < 0.0001 | 0.01 |
LV myocardial perfusion index | 1.86 ± 0.17 | 1.37 ± 0.31 | 1.18 ± 0.26 | 1.49 ± 0.36 | < 0.0001 | 0.2 |
Echocardiography | ||||||
Lateral e′ | 11.8 ± 3.3 | 9.5 ± 2.7 | 9.7 ± 2.5 | 8.6 ± 1.8 a | 0.0002 | 0.0496 |
Septal e′ | 7.4 ± 2.3 | 6.8 ± 1.9 | 5.8 ± 1.5 | 6.1 ± 1.6 | 0.009 | 0.2 |
E/A-ratio | 1.21 IQR1.0–1.67 | 0.90 IQR0.77–1.12 | 0.86 IQR0.68–1.0 | 0.90 IQR0.77–1.15 | < 0.0001 | 0.8 |
Average E/e′ | 8.3 IQR7.0–11.0 | 8.8 IQR7.4–10.7 | 10.2 IQR8.0–12.8 | 9.9 IQR8.7–12.6a | 0.04 | 0.04 |
Data presented as median and interquartile range (IQR) or as nominal values with percentages in parentheses
aIncluding three patients with both ischemic and non-ischemic lesions
bComparison between all three groups as appropriate
cComparison between T2DM patients with non-ischemic LGE vs. T2DM patients without LGE